Publications
By clicking on the links below, you will access a third-party web site. Adherex does not maintain or provide information directly to the third-party sites. Accordingly, Adherex makes no representations or warranties with respect to the information contained on those sites and assumes no responsibility for any information or statements that you may encounter on the Internet outside of our web site.
Targeting N-Cadherin Enhances Antitumor Activity of Cytotoxic Therapies in Melanoma Treatment.
Publication: Cancer Res 2008; 68(10); 1-8.
Authors: Augustine CK, Yoshimoto Y, Gupta M, Zipfel PA, Selim MA, Febbo P, Pendergast AM, Peters WP, Tyler DS
A phase I/II study of systemic ADH-1 in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma
Publication: J Clin Oncol 26: 2008 (May 20 suppl; abstr 9013)
Authors: G. Beasley, N. McMahon, G. Sanders, P. Zipfel, C. Augustine, W. Petros, J. Padussis, M. I. Ross, A. Selim, W. Peters, D. S. Tyler
ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression.
Publication: Int J Cancer. 2008 Jan 1;122(1):71-7.
Authors: Shintani Y, Fukumoto Y, Chaika N, Grandgenett PM, Hollingsworth MA, Wheelock MJ, Johnson KR.
N-cadherin expression in breast cancer: correlation with an aggressive histologic variant - invasive micropapillary carcinoma
Publication: Breast Cancer Research and Treatment, Vol. 94, pp. 225-235, 2005
Authors: C. Nagi, M. Guttman, S. Jaffer, R. Qiao, R. Keren, A. Triana, M. Li, J. Godbold, I. Bleiweiss and R.B. Hazan
Cadherin switch in tumor progression
Publication: Annals of New York Academy of Sciences, Vol. 1014, pp. 155-163, 2004
Authors: R. B. Hazan, R. Qiao, R. Keren, I. Badano and K. Suyama
Cadherins and tumor progression: is it all in a switch?
Publication: Cancer Letter, Vol. 176, pp. 123-128, 2002
Authors: U. Cavallaro, B. Schaffhoser and G. Christofori
A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor
Publication: Cancer Cell, Vol.2, pp. 301-314, 2002
Authors: K. Suyama, I. Shapiro, M. Guttman and R.B. Hazan
N-cadherin as an invasion promoter: a novel target for anti-tumor therapy?
Publication: Current Opinion in Investigational Drugs, Vol. 5, pp. 1274-1278, 2004
Authors: U. Cavallaro
Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion and metastasis
Publication: Journal of Cell Biology, Vol. 148, pp. 779-790, 2000
Authors: R.B. Hazan, G.R. Phillips, R.F. Qiao, L. Norton and S.A. Aaronson
Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough
Publication: Biochemical Biophysica Acta. 1552: 39-45, 2001
Authors: U. Cavallaro and G. Christofori
Cadherins as modulators of celluar phenotype
Publication: Annual Review of Cell and Developmental Biology, Vol. 19, 2003: pp. 207-235
Authors: M.J. Wheelock and K.R. Johnson
Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrmidine dehydrogenase activity
Publication: Journal of Clinical Oncology, Vol. 13, No. 7, 1995: pp. 1663-1670
Authors: M.C. Etienne, S. Ch6radame, J.L. Fischel, P. Formento, O. Dassonville, N. RenBe, M. Schneider,
A. Thyss, F. Demard, and G. Milano
Randomized, open-label, Phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer
Publication: Journal of Clinical Oncology, Vol. 20, Nov. 6, 2002: pp. 1519-1526
Authors: Richard Schilsky, Jeremy Levin, William West, Alfred Wong, Bruce Colwell, Michael Thirwell, Rafat Ansari, William Bell, Robin White, Barbara Yates, Paul McGuirt and Richard Pazdur
A multicenter Phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer
Publication: Annals of Oncology, Vol. 11, pp. 415-420, 2000
Authors: R.L. Schilsky, R. Bukowski, H. Burris III, H. Hochster, M. O'Rourke, J.G. Wall, S. Mani, T. Bonny, J. Levin and J. Hohneker
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer
Publication: Journal of Clinical Oncology, Vol. 16, No. 4, 1998: pp. 1450-1457
Authors: Richard Schilsky, John Hohneker, Mark Ratain, Linda Janisch, Leslie Smetzer, Virgil Sol Lucas, Soo Peang Khor, Robert Diasio, Daniel von Hoff and Howard Burriss III
Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors
Publication: Journal of Clinical Oncology, Vol. 18, No. 23, 2000: pp. 3952-3963
Authors: Jean Grem, Nancy Harold, Jeremy Shapiro, Dao-Qin Bi, Mary Quinn, Suzanne Zentko, Bruce Keith, Michael Hamilton, Brian Monahan, Sean Donavan, Frank Grollman, Geraldine Morrison and Chris Takimoto
5-ethynyluracil: A potent modulator of the pharmcokinetics and anti-tumor efficacy of 5-fluorouracil
Publication: Proceedings of the National Academy of Sciences, Vol. 90, pp: 11064-11068, 1993
Authors: David Baccanari, Stephen Davis, Vincent Knick and Thomas Spector
Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors
Publication: Investigational New Drugs, 18: 383-390, 2002
Authors: Jeremy Levin and John Hohneker
An evolving role for oral fluoropyrmidine drugs
Publication: Journal of Clinical Oncology, Vol. 20, No. 4, 2002: pp. 894-896.
Authors: Robert B. Diasio
Induction of apoptosis in cultured endothelial cells by a cadherin antagonist peptide: involvement in fibroblast growth factor receptor-mediated signaling
Publication: Experimental Cell Research, 2004, Vol. 294, pp: 366-78
Authors: Erez. N, E. Zamir, B.J. Gour, O.W. Blaschuk and B. Geiger
Plasma membrane components of adherens junctions (Review)
Publication: Molecular Membrane Biology, 2002, Vol. 19, pp: 75-80
Authors: Blaschuk, O.W. and T.M. Rowlands
Delayed Sodium Thiosulfate as an Otoprotectant Against Carboplatin-induced Hearing Loss in Patients with Malignant Brain Tumors
Publication: Clinical Cancer Research, 2001, Vol. 7, pp: 493-500
Authors: Nancy D. Doolittle, Leslie L. Muldoon, Robert E. Brummett, Rose Marie Tyson, Cynthia Lacy, Joseph S. Bubalo, Dale F. Kraemer, Michael Heinrich, James A. Henry and Edward A. Neuwelt
A Novel Family of Cyclic Peptide Antagonists Suggests That N-Cadherin Specificity is Determined by Amino Acids that Flank the HAV Motif
Publication: Journal of Biological Chemistry, 2000, Vol. 275, No. 6, pp:4007-4012
Authors: Emma Williams, Gareth Williams, Barbara J. Gour, Orest W. Blaschuk and Patrick Doherty
Cadherins as modulators of angiogenesis and the structural integrity of blood vessels (Review)
Publication: Cancer and Metastasis Reviews, 2000, Vol. 19, pp: 1-5
Authors: Orest W. Blaschuk and Tracey M. Rowlands
First Evidence of Otoprotection Against Carboplatin-induced Hearing Loss in a Two-Compartment System in Patients with Central Nervous System Malignancy Using Sodium Thiosulfate
Publication: Journal of Pharmacology and Experimental Therapeutics, 1998, Vol. 286, pp: 77-84
Authors: Edward A. Neuwelt, Robert E. Brummett, Nancy D. Doolittle, Leslie L. Muldoon, Robert A. Kroll, Michael A. Pagel, Rhonda Dojan, Victoria Church, Laura G. Remsen and Joseph S. Bubalo
Identification of a Cadherin Cell Adhesion Recognition Sequence
Publication: Developmental Biology, 1990, Vol. 139, pp: 227-229
Authors: Orest W. Blaschuk , Robert Sullivan, S. David and Yannick Pouliot
